IL214921A0 - Calcium citrate and calcium lactate formulations for altertion of biophysical properties of mucosal lining - Google Patents

Calcium citrate and calcium lactate formulations for altertion of biophysical properties of mucosal lining

Info

Publication number
IL214921A0
IL214921A0 IL214921A IL21492111A IL214921A0 IL 214921 A0 IL214921 A0 IL 214921A0 IL 214921 A IL214921 A IL 214921A IL 21492111 A IL21492111 A IL 21492111A IL 214921 A0 IL214921 A0 IL 214921A0
Authority
IL
Israel
Prior art keywords
calcium
altertion
biophysical properties
mucosal lining
lactate formulations
Prior art date
Application number
IL214921A
Other languages
English (en)
Original Assignee
Pulmatrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Inc filed Critical Pulmatrix Inc
Publication of IL214921A0 publication Critical patent/IL214921A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL214921A 2009-03-26 2011-09-01 Calcium citrate and calcium lactate formulations for altertion of biophysical properties of mucosal lining IL214921A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16377209P 2009-03-26 2009-03-26
US26774709P 2009-12-08 2009-12-08
PCT/US2010/028914 WO2010111650A2 (en) 2009-03-26 2010-03-26 Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining

Publications (1)

Publication Number Publication Date
IL214921A0 true IL214921A0 (en) 2011-11-30

Family

ID=42635141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214921A IL214921A0 (en) 2009-03-26 2011-09-01 Calcium citrate and calcium lactate formulations for altertion of biophysical properties of mucosal lining

Country Status (11)

Country Link
US (1) US20120083531A1 (pt)
EP (1) EP2410986A2 (pt)
JP (1) JP2012522012A (pt)
KR (1) KR20120015295A (pt)
CN (1) CN102448439A (pt)
AU (1) AU2010229730A1 (pt)
BR (1) BRPI1013872A2 (pt)
CA (1) CA2754684A1 (pt)
IL (1) IL214921A0 (pt)
MX (1) MX2011009956A (pt)
WO (1) WO2010111650A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2315580T3 (da) * 2009-03-26 2012-04-10 Pulmatrix Inc Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
PT106094A (pt) * 2012-01-13 2013-07-15 Hovione Farmaciencia S A Administração por inalação de formulações com dose elevada
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015049519A2 (en) * 2013-10-02 2015-04-09 Vectura Limited Method and apparatus
RU2628800C2 (ru) * 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
EP3240561A4 (en) * 2014-12-29 2018-07-11 Academia Sinica Method for treating influenza a virus infection
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
JP6940416B2 (ja) * 2015-05-01 2021-09-29 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 多剤脆性マトリックス組成物
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
KR20180062063A (ko) 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
CN107648207A (zh) * 2017-10-11 2018-02-02 北京北朋科技有限公司 雾化吸入用柠檬酸盐糖醇溶液
CA3087953C (en) 2018-01-12 2025-11-25 Metimedi Pharmaceuticals Co., Ltd. METHODS OF TREATMENT FOR CHRONIC INFLAMMATORY DISEASES
CN110527628B (zh) * 2019-07-30 2022-05-10 南京农业大学 一种啶虫脒降解菌的保护剂及其制备方法和应用
IT202000005026A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso inalatorio ad azione antivirale

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
KR20040058324A (ko) * 2001-11-26 2004-07-03 다이이찌 산토리 파마 가부시키가이샤 경비흡수용 의약 조성물
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20080125488A1 (en) * 2003-05-01 2008-05-29 Leverve Xavier M Lactate Containing Pharmaceutical Composition and Uses Thereof
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
JP2008507585A (ja) * 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
AU2006247077A1 (en) * 2005-05-18 2006-11-23 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
CN102448438A (zh) * 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
DK2315580T3 (da) * 2009-03-26 2012-04-10 Pulmatrix Inc Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner

Also Published As

Publication number Publication date
JP2012522012A (ja) 2012-09-20
MX2011009956A (es) 2012-01-27
EP2410986A2 (en) 2012-02-01
AU2010229730A1 (en) 2011-10-06
BRPI1013872A2 (pt) 2018-06-19
US20120083531A1 (en) 2012-04-05
KR20120015295A (ko) 2012-02-21
WO2010111650A2 (en) 2010-09-30
CA2754684A1 (en) 2010-09-30
WO2010111650A3 (en) 2010-11-18
CN102448439A (zh) 2012-05-09

Similar Documents

Publication Publication Date Title
IL214921A0 (en) Calcium citrate and calcium lactate formulations for altertion of biophysical properties of mucosal lining
PL2419114T5 (pl) Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej
GB0807224D0 (en) Remineralisation of calcified tissue
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
EP2440220A4 (en) COMPOSITIONS AND METHOD FOR PREPARING COMPOSITIONS FOR PREVENTING AND TREATING HYPERTENSION
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
SG10201402491YA (en) Methods and compositions for diagnosis and treatment of cancer
GB0908193D0 (en) Treatment of disease state
IL236516A0 (en) Methods and preparations for the diagnosis and treatment of cancer
GB0902040D0 (en) Composition for treatment of skin
ZA201200017B (en) Formulations for the treatment of deeep tissue pain
GB2470818B (en) Methods for administration and formulations for the treatment of regional adipose tissue
EP2582235A4 (en) ORAL TREATMENT OF DIGITAL ISCHEMIC LESIONS
IL206491A0 (en) Treatment of produce
EP2405747A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
IL218448A0 (en) Compositions for treatment of neuropathic pain
PL2435026T3 (pl) Leczenie zrostu tkanek
PT3628342T (pt) Compósitos de hidroxiapatita e carbonato de cálcio e métodos relacionados de preparação e utilização
PL2375912T3 (pl) Kompozycje i sposoby leczenia uczucia dyskomfortu gardła
SG10201408187XA (en) Treatment of Bone Fracture
EP2413696A4 (en) COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
HK1165334A (en) Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
PL2536398T3 (pl) Leczenie osteoporozy
PT2453912T (pt) Composição para tratamento de leishmaníase canina e humana